Mazen Madhoun, MD
Hospice and Palliative Medicine · Salem, VANPI 1518127927
Payments from drug & device makers
What this record shows
This record is dominated by education: $111 of the $111 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Teva Pharmaceuticals USA, Inc.. That places this record below the midpoint for hospice and palliative medicine clinicians in VA, where the typical reported total is $111.
Across 1 payment — averaging $111.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$111
What the payments were for
- Education$111100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
How this compares
$111 in reported general payments places this provider in the 50th percentile of 45 hospice and palliative medicine providers in Virginia.
See all hospice and palliative medicine providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,548 | $878,645 |
| TrulicityDulaglutide | 355 | $203,713 |
| AustedoDeutetrabenazine | 42 | $201,644 |
| IngrezzaValbenazine Tosylate | 45 | $190,513 |
| XifaxanRifaximin | 107 | $148,686 |
| JardianceEmpagliflozin | 328 | $116,615 |
| BetaseronInterferon Beta-1b | 11 | $112,943 |
| OzempicSemaglutide | 85 | $87,176 |
| EntrestoSacubitril/Valsartan | 223 | $80,406 |
| XareltoRivaroxaban | 231 | $78,413 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $62,748 |
| JanuviaSitagliptin Phosphate | 178 | $54,779 |
| Divalproex Sodium | 981 | $52,402 |
| Aripiprazole | 464 | $51,499 |
| Tetrabenazine | 18 | $50,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $111 | $201,64442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 45 hospice and palliative medicine providers in Virginia.
Other hospice and palliative medicine in Salem
- Gregory AloufSalem$13K
- Purvi ShahRichmond$9K
- Sarah WestNewport News$3K
- Jessica HeintzFairfax$2K
- Sea KimAlexandria$2K
- Muhammad SiddiquiManassas$948
- Haley VestCharlottesville$534
- Cara JenningsRichmond$458
- Ying LiNorfolk$240
- Prashanta KoiralaWinchester$235
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.